New dermatology portfolio drives Almirall in first nine months
This article was originally published in Scrip
Almirall's new dermatology portfolio helped drive net sales, which reached €685.2 million in the first nine months of 2009, up by 16% compared with the same period last year. The Spanish company's total revenues grew by 18% to €808.7 million.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.